Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents

By Ryan Davis (September 10, 2018, 9:01 PM EDT) -- A split Federal Circuit panel on Monday upheld a judge's decision that four patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra are invalid as obvious, clearing the way for competing generic versions and putting the drug's over $500 million in annual sales in jeopardy....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!